Intra-Cellular TherapiesITCI
About: Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. It maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Employees: 860
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
131% more call options, than puts
Call options by funds: $25.4M | Put options by funds: $11M
127% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 30
50% more funds holding in top 10
Funds holding in top 10: 10 [Q3] → 15 (+5) [Q4]
11% more capital invested
Capital invested by funds: $7.27B [Q3] → $8.08B (+$806M) [Q4]
8% more funds holding
Funds holding: 350 [Q3] → 379 (+29) [Q4]
1% less repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 134
2.68% less ownership
Funds ownership: 93.9% [Q3] → 91.22% (-2.68%) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Mizuho Graig Suvannavejh 38% 1-year accuracy 9 / 24 met price target | 1%upside $132 | Neutral Downgraded | 24 Feb 2025 |
Canaccord Genuity Sumant Kulkarni 25% 1-year accuracy 8 / 32 met price target | 1%upside $132 | Hold Downgraded | 31 Jan 2025 |
RBC Capital Brian Abrahams 15% 1-year accuracy 11 / 71 met price target | 1%upside $132 | Sector Perform Downgraded | 22 Jan 2025 |
Piper Sandler David Amsellem 60% 1-year accuracy 21 / 35 met price target | 1%upside $132 | Neutral Downgraded | 14 Jan 2025 |
Financial journalist opinion
Based on 5 articles about ITCI published over the past 30 days









